All News

pregnant, pregnancy, mother, fertility

Current approach to lupus and pregnancy

Robert Chao, MD

All of us are extremely cautious with lupus patients when it comes to pregnancy. Presentation 6888 (Common issues in pregnancy management in lupus and anti-phospholipid syndrome by Dr. Rebecca Fischer-Betz) was an excellent overview of our current approach to lupus and pregnancy. 

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
DAPSA PsA measure

Q-DAPSA for Measuring Disease Activity in PsA

Rachel Tate, DO

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Read Article
light-bulbs-1125016_640.jpg

Lessons learned in SLE

Janet Pope, MD, MPH, FRCPC

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).

Read Article
audience learn

EULAR 2021 - Day 3 Report

Jack Cush, MD

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article
PSA068.jpg

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Meral K. El Ramahi, MD, FACP, FACR

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
COVID vaccine vials

Israel provides COVID vaccine answers for rheumatic disease patients

David Liew, FRACP

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Read Article
Video: Combination DMARD for Lupus Nephritis: Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021 https://t.co/RGVZ6jukYy https://t.co/PTjSOfM7YQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 ) Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021. https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU

Links:

Dr. John Cush RheumNow ( View Tweet)
Excellent talk on SLE, APS abs pregancy ⭐️pregnancy counseling is important ⭐️aspirin 81mg in all pregnant SLE pts ⭐️do not discontinue HCQ ⭐️stable LN - can switch MMF to AZA Abs#6888 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

On choosing an agent for MTX-IR RA: "(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha #EULAR2021 @RheumNow https://t.co/C45ey1SrA1
David Liew drdavidliew ( View Tweet)
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

Results: MTX vs. PBO ✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001) ✅HR for kidney AE on safety labs: 0.73 (0.59-0.91) ✔️HR for kidney AE clinical events: 0.87 (0.56-1.36) ✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
🤜MTX safe from kidney perspective if baseline CrCl 40+ 🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How does MTX affect kidney function/adverse events? Pre-specified analysis of DBRCT: MTX 15-20mg/wk (n=2391) vs. PBO (n=2395) both with folic acid over median f/u 23 months ✅We demonstrated kidney safety of MTX ⚡️⚡️Also a *suggestion* of LESS decline in eGFR for MTX than PBO https://t.co/SZXloLRmnj

Links:

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy? ⭐️Mean C3 ⬆️28% compared to 1st trimester ⭐️Mean C4 ⬆️ 11% compared to 1st trimester @RheumNow

Eric Dein ejdein1 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×